CN113321724A - Antigenic peptide related to esophageal cancer driver gene mutation and application thereof - Google Patents

Antigenic peptide related to esophageal cancer driver gene mutation and application thereof Download PDF

Info

Publication number
CN113321724A
CN113321724A CN202110598408.3A CN202110598408A CN113321724A CN 113321724 A CN113321724 A CN 113321724A CN 202110598408 A CN202110598408 A CN 202110598408A CN 113321724 A CN113321724 A CN 113321724A
Authority
CN
China
Prior art keywords
esophageal cancer
driver gene
gene mutation
cancer driver
antigenic peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110598408.3A
Other languages
Chinese (zh)
Other versions
CN113321724B (en
Inventor
郝冰娜
赵环
蔡睿
罗夫辛克纳吉
张积仁
李许峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen New Target Biotechnology Co ltd
Original Assignee
Shenzhen New Target Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen New Target Biotechnology Co ltd filed Critical Shenzhen New Target Biotechnology Co ltd
Priority to CN202111360943.1A priority Critical patent/CN114230655A/en
Priority to CN202111360947.XA priority patent/CN114230656A/en
Publication of CN113321724A publication Critical patent/CN113321724A/en
Application granted granted Critical
Publication of CN113321724B publication Critical patent/CN113321724B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention discloses an antigenic peptide related to the mutation of an esophageal cancer driver gene, wherein the esophageal cancer driver gene comprises at least two of EPCAM, MUC1, GPC3, LRP1B, ERBB4 and PREX 2; the sequences of the antigenic peptides are at least two of SEQ No. 1-12; the application of the antigenic peptide is to use the antigenic peptide for inducing and generating specific cytotoxic T cell clone; the antigen peptide has high affinity with MHC I molecules on DC cells, can effectively stimulate and induce to generate specific cytotoxic T lymphocytes, can be used for immune elimination of tumor cells with driving gene mutation related to esophageal cancer, and has good treatment potential.

Description

Antigenic peptide related to esophageal cancer driver gene mutation and application thereof
Technical Field
The invention relates to an antigenic peptide related to esophageal cancer driver gene mutation and application thereof, belonging to the technical field of biological medicines.
Background
Esophageal cancer is a common tumor of the digestive tract, and about 30 million people die of esophageal cancer every year worldwide. The morbidity and mortality varies greatly from country to country. China is one of the high-incidence areas of esophageal cancer in the world, and the average death rate of the esophagus cancer is about 15 ten thousand people every year.
The conventional treatment modalities for esophageal cancer are generally: surgical resection treatment; radiotherapy can improve long-term survival rate but has more complications and unsatisfactory curative effect; chemotherapy: sometimes the efficacy is improved or the symptoms of esophageal cancer patients are relieved and the survival time is prolonged, but hemograms and liver and kidney functions are examined regularly and the drug response is noted.
With the understanding of the nature of tumor-driving gene mutation and personalized precise immune response, a personalized and customized tumor-driving gene mutation-associated peptide antigen is provided as a new concept of tumor-specific new antigen immune cell therapy, and natural T cell immune defense systems of human bodies are induced to selectively destroy tumor-driving gene mutation cells through the unique tumor-driving gene mutation-associated antigen, so that various cancers are effectively prevented from happening, and the technical field is evaluated as ten technical innovation research fields in 2019 of the United states.
However, since the technology requires multidisciplinary, high-technology and multi-platform cooperative research, the antigen peptide related to esophageal cancer driver gene mutation cannot be systematically found and a relatively complete peptide library is established, and thus a therapeutic agent with excellent effect cannot be formed.
Disclosure of Invention
In order to overcome the defects of the prior art, the first object of the present invention is to provide an antigenic peptide related to esophageal cancer driver gene mutation, which has high affinity with MHC I molecules on DC cells, can effectively stimulate and induce the generation of specific Cytotoxic T Lymphocytes (CTLs), can be used for the immune clearance of tumor cells with esophageal cancer driver gene mutation, and has good therapeutic potential.
The second purpose of the invention is to provide an application of the antigen peptide related to the esophageal cancer driver gene mutation.
The first purpose of the invention can be achieved by adopting the following technical scheme: an antigenic peptide associated with a mutation in an esophageal cancer driver gene, wherein the esophageal cancer driver gene is at least two of EPCAM, MUC1, GPC3, LRP1B, ERBB4 and PREX 2.
Wherein, the sequences of the antigenic peptides related to the esophageal cancer driver gene mutation are at least two of SEQ No. 1-12.
The second purpose of the invention can be achieved by adopting the following technical scheme: the application of the antigenic peptide related to the esophageal cancer driver gene mutation is to use the antigenic peptide related to the esophageal cancer driver gene mutation for inducing and generating specific cytotoxic T cell clone.
Or, the application of the antigenic peptide related to the esophagus cancer driving gene mutation, the antigenic peptide related to the esophagus cancer driving gene mutation is used for preparing the human body immune activity regulator capable of inducing specific cytotoxic T cell clone.
Or, the use of the antigenic peptide related to the esophageal cancer driver gene mutation, which is used for preparing a cell culture solution for preventing and interfering the mutation of at least two genes of EPCAM, MUC1, GPC3, LRP1B, ERBB4 and PREX 2.
Or, the application of the antigenic peptide related to the esophageal cancer driver gene mutation, and the antigenic peptide related to the esophageal cancer driver gene mutation is used for preparing the esophageal cancer risk intervention therapeutic agent.
The invention carries out comprehensive research from the starting point of specific cancers, aims at researching the generation mechanism of the esophageal cancer, realizes the elimination of esophageal cancer cells with EPCAM, MUC1, GPC3, LRP1B, ERBB4 and PREX2 esophageal cancer driving gene mutation, can inhibit the growth of tumor cells and prevent the generation of the esophageal cancer. The immunological research proves that the principle that CD8 positive T lymphocyte CTL plays cellular immunity is as follows: CTL cells are activated by recognizing antigen peptides bound to MHC-I molecules, and the activated CTL can kill corresponding target cells to exert an immune surveillance effect.
Compared with the prior art, the invention has the beneficial effects that:
1. the antigenic peptide (neoantigen) related to the esophageal cancer driver gene mutation refers to an antigenic peptide which is expressed by tumor cells and can activate T cells; through high-throughput gene sequencing and data analysis, individual somatic cell mutations of the tumor of a patient are found, antigen peptides related to driving gene mutations are screened out to serve as targets, and the targets are subjected to in vitro chemical synthesis and loaded on antigen-presenting cells (APC), so that T cells are activated to identify various new antigen peptides, and the curative effect of killing the mutated tumor cells is further generated;
2. the antigen peptide related to the esophageal cancer driver gene mutation obtained by screening has high affinity with MHC I molecules on DC cells, can effectively stimulate and induce to generate specific Cytotoxic T Lymphocytes (CTLs) and inhibit the growth of tumor cells, and has good potential of polypeptide vaccines and DC vaccines and good clinical transformation and disease prevention prospects.
Detailed Description
The invention will be further described with reference to specific embodiments:
the antigenic peptides used in the examples in connection with mutations in the esophageal cancer driver gene are shown in table 1:
TABLE 1 antigenic peptide sequences associated with esophageal cancer driver gene mutations
Figure BDA0003090565250000031
Figure BDA0003090565250000041
The establishment of antigenic peptide-specific CTL clones associated with mutations in the esophageal cancer driver gene was performed as follows:
10 of the same healthy donor5An individual CD8+T cell activation by loading 10 antigenic peptides associated with esophageal cancer driver gene mutations42 times of stimulation of Mo-DCs at intervals of 1 week and then 10 times of self-body5The mitomycin C treated PBMC loaded with antigen peptide related to esophageal cancer driver gene mutation is obtained by standard cytotoxic assay screening after 1 stimulation.
T2 cells were loaded with 5uM of the antigen peptide associated with the esophageal cancer driver gene mutation as target cells, and the antigen peptide-specific cytotoxicity of CTL associated with the esophageal cancer driver gene mutation was confirmed by LDH release assay.
Detection of LDH lactate dehydrogenase cytotoxicity:
1) the target cells were adjusted to 5X 10 with RPMI-1640 medium containing 5 vt% calf serum4-2×105/mL；
2) Target cells were added to 96-well round bottom cell culture plates at 100. mu.L per well. 3 effector cells are naturally released into control wells, no target cells are added, and only 100 mu L of culture solution is added;
3) add 100. mu.L of CTL effector cells (CD8+ T cells) to each well, with a ratio of effector cells to target cells of 10: 1; the natural release hole was filled with 100. mu.L of culture medium without effector cells, and 100. mu.L of 1 vt% NP40 was added to the maximum release hole. Each experiment is provided with three multiple wells;
4) placing at 37 ℃ for 5 vt% CO2Culturing for 4-6h in a carbon dioxide incubator;
5) centrifuging the culture plate for 200 Xg 10 min; sucking out 150 microliter of supernatant from each hole, and correspondingly adding the supernatant into another 96-hole enzyme-linked assay plate; to each well of the second plate were added 20. mu.L of a 0.4mol/L lactic acid solution, 20. mu.L of 4 mmol/L2-p-iodophenyl-3-p-chloronitrophenyltetrazole, and 20. mu.L of a reaction solution (0.03 vt% BSA, 2.7U/mL lipoamide dehydrogenase, 4.5mmol/L hydrogenated coenzyme I (NAD +), 1.2 vt% sucrose in PBS) in this order, and the mixture was left at room temperature for 20 min;
6) the optical density (OD value) of each well was measured on an enzyme-linked detector at a detection wavelength of 492nm and a reference wavelength of 650 nm.
The method for establishing the antigen peptide specific CTL clone related to the esophageal cancer driver gene mutation by in vitro induction is adopted, the MHC-I restrictive CTL clone is also established, and the polypeptide specific immune response effect is verified by IFN-gamma release experiments.
IFN- γ release assay:
1) coating antibody, taking 44 uL capture antibody and 12mL coat buff to dilute by 1:250 times, coating the liquid on a 96-well enzyme label plate by 100 uL per well, and standing overnight at 4 ℃;
2) washing the plate for 3 times, preparing washing liquor, adding 50mL of distilled water to prepare 1000mLwash buff, diluting by 1:20 times, and washing the plate for 3 times by using an automatic plate washing machine;
3) blocking 220 mu L of assay dilution in each hole and placing for 1h at room temperature;
4) washing the plate for 3 times;
5) prepare standard, dilute by equal ratio, and establish concentration gradient as blank well, 4.7pg/mL, 9.4pg/mL, 18.8pg/mL, 37.5pg/mL, 75pg/mL, 150pg/mL, 300pg/mL, respectively. And sequentially adding a sample to be detected, the auxiliary hole and the sample with overhigh concentration to be diluted. Standing at room temperature for 2 h;
6) washing the plate for 5 times;
7) preparing a detection antibody (secondary antibody) 48 mu L of detector antibody, adding 12mL of assay solution to prepare a solution, adding 48 mu L of SAV-HRP into the solution when adding the sample, and standing 100 mu L of each well at room temperature for 1 h;
8) washing the plate for 7 times;
9) adding chromogenic substrate streptomycin avidin peroxidase, keeping out of the sun for 30 min;
10) adding the stop solution, and carrying out colorimetric preparation on a standard curve by using 450nm as a measurement wavelength and 620nm as a reference wavelength on an enzyme-linked immunosorbent assay.
The results are shown in Table 2, and the results are absorbance values using PBS phosphate buffer and negative control peptide (control peptide sequence: AAAAAAAAA shown in SEQ ID NO. 13) as controls for IFN-. gamma.release test data for the antigen peptides of SEQ ID NO.1-12, respectively. The experimental data show that the CTL epitope established by the invention is extremely effective, and the predicted result and the experimental result are very good in conformity.
TABLE 1 antigenic peptide IFN-. gamma.Release test results (absorbance values)
Figure BDA0003090565250000061
Figure BDA0003090565250000071
Combining at least two antigenic peptides:
combination 1: SEQ ID NO.3 and SEQ ID NO. 11;
and (3) combination 2: SEQ ID NO.4, SEQ ID NO.9, SEQ ID NO.3 and SEQ ID NO. 11;
and (3) combination: SEQ ID NO.3, SEQ ID NO.5, SEQ ID NO.9, SEQ ID NO.11 and SEQ ID NO. 12;
IFN-gamma release experiments were performed with the above three antigen peptide combinations, with PBS phosphate buffer and negative control peptide (control peptide sequence: AAAAAAAAA shown in SEQ ID NO. 13) as controls, and the experimental results were absorbance values, and the results are shown in Table 3.
TABLE 3 IFN-. gamma.Release test results (absorbance values) for antigen peptide combinations
Combination of Antigenic peptides PBS control Negative control
Combination 1 570 29 34
Combination 2 585 31 40
Combination 3 590 29 35
Therefore, at least two of the above antigenic peptides related to esophageal cancer driver gene mutation are co-cultured with cytotoxic T lymphocytes through dendritic cell presentation, and the cytotoxic T lymphocytes specific to the antigenic peptides can be obtained through induced screening. The antigen specific cytotoxic T lymphocyte can be used for immune elimination of tumor cells with driving gene mutation related to esophageal cancer and prevention of related diseases, especially tumor diseases.
At least two of the antigen peptides and Dendritic Cells (DC) are loaded and returned for transfusion, and the antigen peptides can be used as DC vaccine for disease prevention, stimulate organisms to generate polypeptide specificity anti-cytotoxic T cells related to the esophageal cancer driver gene mutation, and further realize the prevention of diseases related to the esophageal cancer driver gene mutation.
The antigen peptide related to the esophageal cancer driver gene mutation has the advantages of short length, small chemical synthesis difficulty, capability of directly synthesizing to obtain a high-purity product, greatly reduced application cost, definite effect and good application potential.
Various other changes and modifications to the above-described embodiments and concepts will become apparent to those skilled in the art from the above description, and all such changes and modifications are intended to be included within the scope of the present invention as defined in the appended claims.
SEQUENCE LISTING
<110> Shenzhen City New Targeted Biotech Limited
<120> antigenic peptide related to esophageal cancer driver gene mutation and application thereof
<130> 2021
<160> 13
<170> PatentIn version 3.5
<210> 1
<211> 9
<212> PRT
<213> Artificial Synthesis (Artificial Sequence)
<400> 1
Leu Gln Lys Glu Ile Thr Thr Arg Tyr
1 5
<210> 2
<211> 9
<212> PRT
<213> Artificial Synthesis (Artificial Sequence)
<400> 2
Lys Glu Ile Thr Thr Arg Tyr Gln Leu
1 5
<210> 3
<211> 9
<212> PRT
<213> Artificial Synthesis (Artificial Sequence)
<400> 3
Asp Thr Tyr His Pro Met Ser Glu Tyr
1 5
<210> 4
<211> 10
<212> PRT
<213> Artificial Synthesis (Artificial Sequence)
<400> 4
Ser Leu Glu Asp Pro Ser Thr Asp Tyr Tyr
1 5 10
<210> 5
<211> 9
<212> PRT
<213> Artificial Synthesis (Artificial Sequence)
<400> 5
Gly Glu Phe Phe Thr Asp Val Ser Leu
1 5
<210> 6
<211> 9
<212> PRT
<213> Artificial Synthesis (Artificial Sequence)
<400> 6
Lys Ser Leu Gln Val Thr Arg Ile Phe
1 5
<210> 7
<211> 10
<212> PRT
<213> Artificial Synthesis (Artificial Sequence)
<400> 7
Trp Thr Asp Ala Arg Ser Asp Ala Ile Tyr
1 5 10
<210> 8
<211> 9
<212> PRT
<213> Artificial Synthesis (Artificial Sequence)
<400> 8
Met Ile Asp Pro Thr Lys Ala Arg Tyr
1 5
<210> 9
<211> 10
<212> PRT
<213> Artificial Synthesis (Artificial Sequence)
<400> 9
Ala Pro Glu Arg Ser Pro Arg Gly Glu Leu
1 5 10
<210> 10
<211> 10
<212> PRT
<213> Artificial Synthesis (Artificial Sequence)
<400> 10
Lys Met Pro Ile Lys Trp Met Ala Leu Glu
1 5 10
<210> 11
<211> 9
<212> PRT
<213> Artificial Synthesis (Artificial Sequence)
<400> 11
Thr Val Asp Asn Val His Leu Glu Tyr
1 5
<210> 12
<211> 9
<212> PRT
<213> Artificial Synthesis (Artificial Sequence)
<400> 12
Asn Thr Asp Val Pro Leu Glu Gly Tyr
1 5
<210> 13
<211> 9
<212> PRT
<213> Artificial Synthesis (Artificial Sequence)
<400> 13
Ala Ala Ala Ala Ala Ala Ala Ala Ala
1 5

Claims (6)

1. An antigenic peptide associated with a mutation in an esophageal cancer driver gene, wherein said esophageal cancer driver gene is at least two of EPCAM, MUC1, GPC3, LRP1B, ERBB4 and PREX 2.
2. The antigenic peptides associated with esophageal cancer driver gene mutation of claim 1, wherein said antigenic peptides associated with esophageal cancer driver gene mutation have at least two of the sequences set forth in SEQ nos. 1-12.
3. Use of the antigenic peptide associated with esophageal cancer driver gene mutation of claim 1 for inducing the generation of specific cytotoxic T cell clones.
4. Use of the antigenic peptide associated with esophageal cancer driver gene mutation of claim 1 in the preparation of a modulator of human immune activity that induces the production of specific cytotoxic T cell clones.
5. Use of the antigenic peptide related to the esophageal cancer driver gene mutation of claim 1 for the preparation of a cell culture solution for the prevention and intervention of mutations in at least two genes selected from EPC AM, MUC1, GPC3, LRP1B, ERBB4 and PREX 2.
6. Use of the antigenic peptide related to the esophageal cancer driver gene mutation according to claim 1 for preparing an esophageal cancer risk intervention therapeutic agent.
CN202110598408.3A 2021-03-24 2021-05-28 Antigenic peptide related to esophageal cancer driver gene mutation and application thereof Active CN113321724B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202111360943.1A CN114230655A (en) 2021-03-24 2021-05-28 Antigenic peptide combination related to esophageal cancer driver gene mutation and application thereof
CN202111360947.XA CN114230656A (en) 2021-03-24 2021-05-28 Antigenic peptide combination related to esophageal cancer driver gene mutation and application thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110316276 2021-03-24
CN2021103162760 2021-03-24

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202111360947.XA Division CN114230656A (en) 2021-03-24 2021-05-28 Antigenic peptide combination related to esophageal cancer driver gene mutation and application thereof
CN202111360943.1A Division CN114230655A (en) 2021-03-24 2021-05-28 Antigenic peptide combination related to esophageal cancer driver gene mutation and application thereof

Publications (2)

Publication Number Publication Date
CN113321724A true CN113321724A (en) 2021-08-31
CN113321724B CN113321724B (en) 2022-02-01

Family

ID=77422511

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202111360943.1A Pending CN114230655A (en) 2021-03-24 2021-05-28 Antigenic peptide combination related to esophageal cancer driver gene mutation and application thereof
CN202111360947.XA Pending CN114230656A (en) 2021-03-24 2021-05-28 Antigenic peptide combination related to esophageal cancer driver gene mutation and application thereof
CN202110598408.3A Active CN113321724B (en) 2021-03-24 2021-05-28 Antigenic peptide related to esophageal cancer driver gene mutation and application thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202111360943.1A Pending CN114230655A (en) 2021-03-24 2021-05-28 Antigenic peptide combination related to esophageal cancer driver gene mutation and application thereof
CN202111360947.XA Pending CN114230656A (en) 2021-03-24 2021-05-28 Antigenic peptide combination related to esophageal cancer driver gene mutation and application thereof

Country Status (1)

Country Link
CN (3) CN114230655A (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1252076A (en) * 1997-04-14 2000-05-03 麦可麦脱生物药学研究有限公司 Production of antihuman antigen receptors and use thereof
CN1324406A (en) * 1998-10-30 2001-11-28 梅纳利尼研究所股份公司 DNA molecules encoding MUC-1 and use thereof in tumor vaccination
US20050282744A1 (en) * 2003-07-11 2005-12-22 Tony Hollingsworth Compositions and methods for preventing or treating cancer
CN1753994A (en) * 2003-02-28 2006-03-29 葛兰素集团有限公司 Vaccines
US20070243201A1 (en) * 2003-06-02 2007-10-18 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag Method for Selecting Epitopes for Immunotherapy
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
CN108025048A (en) * 2015-05-20 2018-05-11 博德研究所 Shared neoantigen
CN111433355A (en) * 2017-08-10 2020-07-17 古德T细胞有限公司 Method of activating T cells for cancer therapy

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1252076A (en) * 1997-04-14 2000-05-03 麦可麦脱生物药学研究有限公司 Production of antihuman antigen receptors and use thereof
CN1324406A (en) * 1998-10-30 2001-11-28 梅纳利尼研究所股份公司 DNA molecules encoding MUC-1 and use thereof in tumor vaccination
CN1753994A (en) * 2003-02-28 2006-03-29 葛兰素集团有限公司 Vaccines
US20070243201A1 (en) * 2003-06-02 2007-10-18 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag Method for Selecting Epitopes for Immunotherapy
US20050282744A1 (en) * 2003-07-11 2005-12-22 Tony Hollingsworth Compositions and methods for preventing or treating cancer
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
CN108025048A (en) * 2015-05-20 2018-05-11 博德研究所 Shared neoantigen
CN111433355A (en) * 2017-08-10 2020-07-17 古德T细胞有限公司 Method of activating T cells for cancer therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRACHA SHRAIBMAN等: "Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma", 《MOLECULAR & CELLULAR PROTEOMICS》 *

Also Published As

Publication number Publication date
CN114230655A (en) 2022-03-25
CN114230656A (en) 2022-03-25
CN113321724B (en) 2022-02-01

Similar Documents

Publication Publication Date Title
EP2228072B1 (en) Cancer vaccine composition
JP3825467B2 (en) Selected immunotherapy with interleukin-7
TWI523660B (en) Cell cycle associated with a peptide and a medicament containing it
US9415096B2 (en) FOXM1 peptide and medicinal agent comprising the same
Lin et al. A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells
MX2007006717A (en) Alpha thymosin peptides as cancer vaccine adjuvants.
CN107001418A (en) Come from HSP70 peptide, the manufacture method for being used to treat or prevent the medical composition, immune inducing agent and antigen presenting cell of cancer using it
CN113321724B (en) Antigenic peptide related to esophageal cancer driver gene mutation and application thereof
CN113321720B (en) Antigenic peptide combination related to liver cancer driver gene mutation and application thereof
CN113173986B (en) Antigenic peptide related to lung cancer driver gene mutation and application thereof
CN113173985A (en) Antigenic peptide related to colorectal cancer driver gene mutation and application thereof
CN113307859B (en) Antigenic peptide combination related to breast cancer driver gene mutation and application thereof
CN109311955B (en) Novel tumor specific polypeptide and application thereof
ES2554981T3 (en) New immunotherapy against neuronal and brain tumors
CN116948004B (en) Tumor new antigen polypeptide aiming at CTNNB1 gene H36P mutation and application thereof
CN108250266A (en) A kind of restricted GPC3 sources property polypeptide of HLA-A11 and include its vaccine
CN107188959B (en) Antigenic peptide T790M-6 and application thereof in preparation of medicines for treating non-small cell lung cancer
CN107188958B (en) Antigenic peptide T790M-5 and application thereof in preparation of medicines for treating non-small cell lung cancer
CN117024522A (en) Tumor neoantigen polypeptide aiming at PIK3CA gene E545K mutation and application thereof
CN116041424A (en) Tumor-associated gene BCL6 mutant short peptide and application thereof in tumor vaccine
CN106117335A (en) The CTL of tumor antigen survivin identifies epitope peptide and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20221207

Address after: 200120 3rd floor, no.665 Zhangjiang Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai

Patentee after: Shanghai Baoyiren Biomedical Co.,Ltd.

Address before: 518000 b1-701-98, building B, Kexing Science Park, 15 Keyuan Road, Science Park community, Yuehai street, Nanshan District, Shenzhen City, Guangdong Province

Patentee before: Shenzhen new target Biotechnology Co.,Ltd.

TR01 Transfer of patent right

Effective date of registration: 20240605

Address after: 518000 b1-701-98, building B, Kexing Science Park, 15 Keyuan Road, Science Park community, Yuehai street, Nanshan District, Shenzhen City, Guangdong Province

Patentee after: Shenzhen new target Biotechnology Co.,Ltd.

Country or region after: China

Address before: 200120 3rd floor, no.665 Zhangjiang Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai

Patentee before: Shanghai Baoyiren Biomedical Co.,Ltd.

Country or region before: China